I farmaci biologici nelle malattie infiammatorie croniche intestinali

Luisa Spina; Luca Pastorelli; Germana De Nucci; Flaminia Cavallaro; Gian Eugenio Tontini; Nadia Munizio; Maurizio Vecchi

I farmaci biologici nelle malattie infiammatorie croniche intestinali

Translated title of the contribution: Biologic therapy in inflammatory bowel disease

Luisa Spina, Luca Pastorelli, Germana De Nucci, Flaminia Cavallaro, Gian Eugenio Tontini, Nadia Munizio, Maurizio Vecchi

IRCCS Policlinico San Donato

Research output: Contribution to journal › Article › peer-review

Abstract

The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.

Translated title of the contribution	Biologic therapy in inflammatory bowel disease
Original language	Italian
Pages (from-to)	179-183
Number of pages	5
Journal	Giornale Italiano di Endoscopia Digestiva
Volume	36
Issue number	3
Publication status	Published - Sep 2013

ASJC Scopus subject areas

Gastroenterology
Radiology Nuclear Medicine and imaging

Cite this

@article{261ea2547de74494a9e3d95eb4c6a584,

title = "I farmaci biologici nelle malattie infiammatorie croniche intestinali",

abstract = "The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.",

keywords = "Adalimumab, Crohn's disease, Infliximab, Ulcerative colitis",

author = "Luisa Spina and Luca Pastorelli and {De Nucci}, Germana and Flaminia Cavallaro and Tontini, {Gian Eugenio} and Nadia Munizio and Maurizio Vecchi",

year = "2013",

month = sep,

language = "Italian",

volume = "36",

pages = "179--183",

journal = "Giornale Italiano di Endoscopia Digestiva",

issn = "0394-0225",

publisher = "Area Qualita Srl",

number = "3",

}

TY - JOUR

T1 - I farmaci biologici nelle malattie infiammatorie croniche intestinali

AU - Spina, Luisa

AU - Pastorelli, Luca

AU - De Nucci, Germana

AU - Cavallaro, Flaminia

AU - Tontini, Gian Eugenio

AU - Munizio, Nadia

AU - Vecchi, Maurizio

PY - 2013/9

Y1 - 2013/9

N2 - The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.

AB - The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.

KW - Adalimumab

KW - Crohn's disease

KW - Infliximab

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84886010950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886010950&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:84886010950

VL - 36

SP - 179

EP - 183

JO - Giornale Italiano di Endoscopia Digestiva

JF - Giornale Italiano di Endoscopia Digestiva

SN - 0394-0225

IS - 3

ER -

I farmaci biologici nelle malattie infiammatorie croniche intestinali

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this